Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints

Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology

---

Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 11 days

Related Stories

---

• Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 11 days
• Cancer Research UK campaign clears £250M milestone for research / 14 days
• Household cats reveal human cancer gene parallels and treatment clues / 19 days
• FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
• FDA rejects Corcept’s cortisol modulator triggering setback / 2 months
• FDA approves Rucaparib for advanced prostate cancer / 2 months
• FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 2 months

Related Tags

---

StackHealth Time Machine

---